Department of Clinical Pharmacology of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
J Tradit Chin Med. 2020 Apr;40(2):167-187.
To address the optimal Chinese herbal injections (CHIs) against liver cancer, the present network Meta-analysis is designed to investigate the comparative efficacy and safety of different CHIs.
Several electronic databases were searched up to June 1st, 2017. The quality assessment was conducted and network Meta-analysis was performed to compare the efficacy and safety of different CHIs plus transcatheter hepatic arterial chemoembolization (TACE). Primary outcomes were 1-year and 2-year survival rate, the secondary outcomes includes the clinical effective rate, performance status and the adverse reactions (ADRs). Data analysis was applied Stata 13.0 and WinBUGS 1.4 software.
A total of 105 randomized controlled trials (RCTs) were identified for inclusion in this analysis, with data for 7683 patients and 13 CHIs. The results suggested that Javanica oil emulsion, Huachansu injection plus TACE were more favorable for 1-year and 2-year survival rate than other CHIs. Kanglaite, Astragalus polysaccharide injection plus TACE showed superiority in the clinical effective rate and performance status over other CHIs. And Shenmai injection plus TACE was superior to reducing ADRs than other CHIs for patients with liver cancer.
Our findings indicated that receiving CHIs combined with TACE may have therapeutic benefits for patients with liver cancer in improving survival rate, clinical effective rate, the performance status and alleviating the ADRs.
为了找到治疗肝癌的最佳中草药注射液(CHIs),本网络荟萃分析旨在研究不同 CHIs 的疗效和安全性。
截至 2017 年 6 月 1 日,我们检索了多个电子数据库。对纳入的研究进行质量评价,并进行网络荟萃分析,比较不同 CHIs 联合经导管肝动脉化疗栓塞术(TACE)的疗效和安全性。主要结局为 1 年和 2 年生存率,次要结局包括临床有效率、体力状况和不良反应(ADRs)。数据分析采用 Stata 13.0 和 WinBUGS 1.4 软件。
共纳入 105 项随机对照试验(RCTs),共纳入 7683 例患者和 13 种 CHIs。结果表明,鸦胆子油乳注射液、华蟾素注射液联合 TACE 较其他 CHIs 更有利于提高 1 年和 2 年生存率。康莱特注射液、黄芪多糖注射液联合 TACE 在临床有效率和体力状况方面优于其他 CHIs。参麦注射液联合 TACE 在降低肝癌患者 ADRs 方面优于其他 CHIs。
我们的研究结果表明,CHIs 联合 TACE 可能对改善肝癌患者的生存率、临床有效率、体力状况和减轻不良反应具有治疗益处。